ARTICLE | Clinical News

Viramune XR nevirapine: Phase III data

August 2, 2010 7:00 AM UTC

In the double-blind, double-dummy, active-controlled Phase III VERxVE trial in 1,011 treatment-naïve HIV patients, once-daily 400 mg Viramune XR was non-inferior to twice-daily immediate-release 200 mg Viramune IR on the primary endpoint of proportion of patients achieving a confirmed virologic response through week 48 (81% vs. 75.9%). Furthermore, response rates in patients with baseline HIV RNA levels >100,000 copies/mL were 73% and 71% for Viramune XR and IR, respectively. In patients with baseline HIV RNA levels <=100,000 copies/mL, response rates were 79% and 86%, respectively. ...